Mirum Pharmaceuticals, Inc. (MIRM) Financial Statements
Mirum Pharmaceuticals, Inc. (MIRM) reported trailing twelve-month revenue of $618.1M (up 44.0% year on year) and net income of -$860.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$228.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MIRMMirum Pharmaceuticals, Inc.Follow MIRM — free
—
Price chart with a free account
- Market cap
- 5.2B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 17 Nov, in 24 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.02 | 0.08 | 0.19 | 0.34 | 0.52 | 0.62 | |
| Gross profit | — | — | 0.14 | 0.26 | 0.42 | 0.51 | |
| Research & development | 0.13 | 0.11 | 0.10 | 0.14 | 0.19 | 0.28 | |
| Operating income | -0.17 | -0.13 | -0.11 | -0.09 | -0.02 | -0.83 | |
| Pre-tax income | -0.08 | -0.14 | -0.16 | -0.09 | -0.02 | -0.86 | |
| Income tax | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net income | -0.08 | -0.14 | -0.16 | -0.09 | -0.02 | -0.86 | |
| Diluted EPS ($) | -2.77 | -4.02 | -4.00 | -1.85 | -0.47 | -13.58 | |
| Diluted shares (bn) | — | 0.034 | 0.041 | 0.048 | 0.050 | — |
USD billions · SEC XBRL
Mirum Pharmaceuticals, Inc. — questions
- What is Mirum Pharmaceuticals, Inc.'s revenue?
- $618.1M over the twelve months to 2026-06-30, up 44.0% year on year, from its 10-Q and 10-K filings.
- What is Mirum Pharmaceuticals, Inc.'s net income?
- -$860.2M over the twelve months to 2026-06-30.
- What is Mirum Pharmaceuticals, Inc.'s free cash flow?
- -$228.7M over the twelve months to 2026-06-30.
- What are Mirum Pharmaceuticals, Inc.'s diluted earnings per share?
- $-13.58 over the twelve months to 2026-06-30.
Every figure on this page comes from Mirum Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.